May 1976

Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients

Author Affiliations

From the Department of Neurobiology, Clinical Research Institute of Montreal, the Department of Medicine, University of Montreal, and the Hôtel-Dieu Hospital, Montreal.

Arch Neurol. 1976;33(5):333-338. doi:10.1001/archneur.1976.00500050019004

• The clinical course and the side effects of high-level levodopa therapy over a six-year period were studied in 80 severely akinetic parkinsonian patients treated for the first time before June 1968. Levodopa improved the quality of life in greater than 53% of patients, but failed to modify the progression of the disease or change the prognosis. Seventeen "idiopathic Parkinson" patients died after a duration of illness of 9.5 years. Despite the drawbacks, levodopa is still the best available treatment for akinetic parkinsonism.